特一药业：10月23日召开董事会会议

Core Viewpoint - The company Te Yi Pharmaceutical (SZ 002728) announced the convening of its sixth board meeting to review the third quarter report for 2025, highlighting its financial performance and business structure [1]. Financial Performance - For the first half of 2025, Te Yi Pharmaceutical reported that its revenue composition was as follows: pharmaceutical manufacturing accounted for 98.52%, pharmaceutical commerce for 0.87%, and chemical products and others for 0.61% [1]. - As of the report date, the market capitalization of Te Yi Pharmaceutical was 5.5 billion yuan [1].